
3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5. SOLE VOTING POWER

0

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

6. SHARED VOTING POWER

971,909

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

971,909

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

971,909

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |__|

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.87%

12. TYPE OF REPORTING PERSON*

PN

CUSIP No. 584688105

13G

Page 3 of 11 Pages

1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Partners, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) |__|
(b) |X|

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Edgar Filing: MEDICINES CO /DE - Form SC 13G/A

Delaware

5. SOLE VOTING POWER

0

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

6. SHARED VOTING POWER

971,909

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

971,909

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

971,909

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |__|

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.87%

12. TYPE OF REPORTING PERSON*

PN

CUSIP No. 584688105 13G Page 4 of 11 Pages

1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Management Company, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) |__|
(b) |X|

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

New York

5. SOLE VOTING POWER

0

NUMBER OF

6. SHARED VOTING POWER

Edgar Filing: MEDICINES CO /DE - Form SC 13G/A

SHARES
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 1,765,862

7. SOLE DISPOSITIVE POWER
0

8. SHARED DISPOSITIVE POWER
1,765,862

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,765,862

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.41%

12. TYPE OF REPORTING PERSON*

PN

CUSIP No. 584688105

13G

Page 5 of 11 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield International Limited

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

5. SOLE VOTING POWER

0

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 1,765,862

6. SHARED VOTING POWER

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

Edgar Filing: MEDICINES CO /DE - Form SC 13G/A

1,765,862

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,765,862

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.41%

12. TYPE OF REPORTING PERSON*

CO

CUSIP No. 584688105

13G

Page 6 of 11 Pages

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

James E. Flynn

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5. SOLE VOTING POWER

0

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

6. SHARED VOTING POWER

2,737,771

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

2,737,771

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,737,771

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

Edgar Filing: MEDICINES CO /DE - Form SC 13G/A

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.28%

12. TYPE OF REPORTING PERSON*

IN

Page 7 of 11 Pages

CUSIP No. 584688105

Item 1(a). Name of Issuer:

The Medicines Company (the "Company")

Item 1(b). Address of Issuer's Principal Executive Offices:

8 Campus Drive, Parsippany, New Jersey 07054

Item 2(a). Name of Person Filing:

James E. Flynn, Deerfield Capital, L.P., Deerfield Partners, L.P.,
Deerfield Management Company, L.P., Deerfield International Limited

Item 2(b). Address of Principal Business Office, or if None, Residence:

James E. Flynn, Deerfield Capital, L.P., Deerfield Partners, L.P.,
Deerfield Management Company, L.P., 780 Third Avenue, 37th Floor,
New York, NY 10017, Deerfield International Limited, c/o Bisys
Management, Bison Court, Columbus Centre, P.O. Box 3460, Road Town,
Tortola, British Virgin Islands

Item 2(c). Citizenship:

Deerfield Capital, L.P. and Deerfield Partners, L.P.
- Delaware limited partnerships, Deerfield Management Company, L.P.
- New York limited partnership, Deerfield
International Limited- British Virgin Islands corporation

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number:

584688105

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b)
or (c), Check Whether the Person Filing is a:

Edgar Filing: MEDICINES CO /DE - Form SC 13G/A

- (a) Broker or dealer registered under Section 15 of the Exchange Act.
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) Investment company registered under Section 8 of the Investment Company Act.
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

Page 8 of 11 Pages

- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

Deerfield Capital, L.P. - 971,909 shares
Deerfield Partners, L.P. - 971,909 shares
Deerfield Management Company, L.P. - 1,765,862 shares
Deerfield International Limited - 1,765,862 shares
James E. Flynn - 2,737,771 shares

(b) Percent of class:

Deerfield Capital, L.P. - 1.87%
Deerfield Partners, L.P. - 1.87%
Deerfield Management Company, L.P. - 3.41%
Deerfield International Limited - 3.41%
James E. Flynn - 5.28%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote: All Reporting Persons 0

(ii) Shared power to vote or to direct the vote

Deerfield Capital,	-----
L.P. - 971,909	
Deerfield Partners,	
L.P. - 971,909	
Deerfield	
Management Company,	
L.P. - 1,765,862	

Edgar Filing: MEDICINES CO /DE - Form SC 13G/A

Deerfield
International
Limited - 1,765,862
James E. Flynn -
2,737,771

Page 9 of 11 Pages

- (iii) Sole power to dispose or to direct the disposition of All Reporting Persons - 0

- (ii) Shared power to vote or to direct the vote Deerfield Capital,
L.P. - 971,909
Deerfield Partners,
L.P., - 971,909
Deerfield
Management Company,
L.P. - 1,765,862
Deerfield
International
Limited - 1,765,862
James E. Flynn -
2,737,771

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following |_|.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DEERFIELD CAPITAL, L.P.

By: J.E. Flynn Capital LLC,
General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD PARTNERS, L.P.

By: Deerfield Capital, L.P.

By: J.E. Flynn Capital LLC,
General Partner

Edgar Filing: MEDICINES CO /DE - Form SC 13G/A

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC
General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD INTERNATIONAL LIMITED

By: Deerfield Management Company

By: Flynn Management LLC,
General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

JAMES E. FLYNN

/s/ Darren Levine

Darren Levine, Attorney-In-Fact

Date: February 14, 2008

Exhibit List

Exhibit A . Joint Filing Agreement.

Exhibit B. Item 8 Statement.

Exhibit C. Power of Attorney. (Previously filed as Exhibit 24 to a Form 4 with regard to PAR Pharmaceutical Companies, Inc. filed with the Commission on February 1, 2007 by Deerfield Capital L.P.; Deerfield Partners, L.P.; Deerfield Management Company, L.P.; Deerfield International Limited; Deerfield Special Situations Fund, L.P.; Deerfield Special Situations Fund International Limited; and James E. Flynn.)

Exhibit A

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of The Medicines Company shall be filed on behalf of the undersigned.

DEERFIELD CAPITAL, L.P.

By: J.E. Flynn Capital LLC,

Edgar Filing: MEDICINES CO /DE - Form SC 13G/A

General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD PARTNERS, L.P.

By: Deerfield Capital, L.P.

By: J.E. Flynn Capital LLC,
General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC
General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

DEERFIELD INTERNATIONAL LIMITED

By: Deerfield Management Company

By: Flynn Management LLC,
General Partner

By: /s/ Darren Levine

Darren Levine, Authorized Signatory

JAMES E. FLYNN

/s/ Darren Levine

Darren Levine, Attorney-In-Fact

Exhibit B

Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a "group" with one another for purposes of Section 13(d) (3) of the Securities Exchange Act of 1934.